Minji Park

Title: Minji Park: Innovation in Antibody-Drug Conjugates

Introduction

Minji Park is a notable inventor based in Daejeon, South Korea. With a focus on biomedicine, she has made significant contributions to the field through her innovative work on antibody-drug conjugates.

Latest Patents

Minji Park holds a patent for an "Antibody-drug conjugate comprising antibody against human ROR1 and use for the same." This invention pertains to novel antibody-drug conjugates (ADCs) that target ROR1, along with the active metabolites of such ADCs. It encompasses methods for their preparation and highlights their potential uses in the treatment and prevention of diseases, particularly those linked with the over-expression of ROR1, such as cancer. The patent specifies an antibody that binds to ROR1 or an antigen-binding fragment, alongside pharmaceutical compositions that integrate these elements.

Career Highlights

Throughout her career, Minji Park has been associated with notable companies in the biopharmaceutical sector, including Legochem Biosciences, Inc. and Abl Bio Inc. These positions have allowed her to work at the forefront of drug development, contributing to novel therapeutic solutions that address critical health challenges.

Collaborations

Minji has collaborated with talented individuals in her field, including coworkers Yun-Hee Park and Ho Young Song. These partnerships have likely fostered the exchange of ideas and innovation, enhancing the impact of her work within the research community.

Conclusion

Minji Park stands out as an influential inventor in the realm of antibody-drug conjugates, demonstrating a commitment to developing effective therapies for serious diseases. Her contributions not only underline the importance of innovation in biomedical research but also highlight collaborative efforts that drive the industry forward.